On 24 December 2024, Rhythm Biosciences completed an asset acquisition agreement for the geneType™ business assets, with business integration currently underway.
To learn more about Rhythm, please visit https://rhythmbio.com/
Under the geneType™ product series, clinicians, scientists and technicians are working to develop the next generation of integrated predictive genetic testing and assessment tools – empowering physicians and patients to proactively manage health.
Rhythm Biosciences is transforming cancer diagnostics through innovative diagnostic technologies that predict, detect, characterise, and support early intervention. Our mission goes beyond testing, we’re creating a comprehensive approach to understanding cancer risk, enabling earlier treatment, and ultimately saving lives.
These are more than just words on a page. Our team, from the top down, makes a conscious decision to integrate our company values into our decision making and practices.
Accelerating the world’s transition to gene-based healthcare.
A more complete picture of disease risk, incorporating genetic & clinical risk factors.
Setting clinical, safety and ethical standards to ensure the best health outcomes.
Leaders in breast and colorectal cancer integrated risk assessment, geneType™ continues to expand our clinical-grade assessments into new cancers and chronic conditions.
We are evolving modern medicine to meet clinical needs.
Our personalized risk assessments provide a more complete picture, incorporating polygenic and clinical risk factors in one comprehensive assessment.
We lead the way in clinical integration of polygenic risk by creating proprietary algorithms that are specifically calibrated to the general population. All of our disease-specific tests outperform their respective clinical gold-standard risk models.
Our technology is designed to provide clinicians with absolute risk scores that simplify the complex integration of risk factors and ultimately enable actionable recommendations.
geneType™ empowers individuals and their clinicians to adopt a personalized health approach to disease screening, risk-reduction and prevention.
The human impact and potential applications for genetic integration into clinical care are immense.
geneType™ are at the forefront of the genetic revolution – expanding our pipeline of clinical risk assessment products to a broader range of cancers and chronic conditions.
International collaborations with leading clinicians, through our clinical research and scientific advisory board, we aim to democratize genomics. Leveraging technology, software and processes to make integrated genetic risk assessments an integral part of preventive healthcare and the standard-of-care in modern medicine. We’re working hard to deliver a more efficient, integrated and personalized approach.
Unequalled experience
20+ years of experience, tracing back to the human genome project.